Chirag R Patel, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1136 Cleveland Ave Ste 221, East Point, GA 30344 Phone: 404-761-1550 Fax: 678-233-1633 |
News Archive
A new study published in the British Medical Journal December 2019 suggests a novel risk factor for heart disease – the season in which the individual is born. The large study carried out in the US shows that people born in either spring or summer had a significant, though slight, increase in the risk of fatal heart disease, when compared to the autumn-born. Why this should be so is unknown as of now.
OrbusNeich announced that clinical data presented at the Joint Intervention Meeting (JIM) 2010 in Rome provide further evidence that the company's Genous stent could be a treatment of choice for patients not suitable for long term dual antiplatelet therapy. The investigator initiated, 50 patient, multicenter study evaluated the safety of patients receiving only 10 days dual antiplatelet therapy undergoing stenting with the Genous Bio-engineered R stent. The primary endpoint was the absence of stent thrombosis or any occlusion within three months.
American CareSource Holdings Inc. today announced second quarter 2010 revenues of $16.0 million compared to $17.1 million in the corresponding prior year quarter. Net income for the second quarter 2010 was $299,000, or $0.02 per diluted share, compared to $534,000, or $0.01 per diluted share, in the corresponding prior year quarter. Net income for the second quarter 2010 included a federal income tax provision of $137,000, or $0.01 per diluted share, which was not included in net income for the second quarter 2009.
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced the treatment of its first patient in a multicentre, open, non-comparative Phase III study to investigate the efficacy, safety, and pharmacokinetics of two subcutaneous (SC) injections of Debio 8206 (triptorelin pamoate 22.5 mg 6-month formulation) in patients with advanced prostate cancer.
› Verified 3 days ago